The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: VA-HIT: A Randomized Controlled Trial
Abstract
CONTEXT: A low plasma level of high-density lipoprotein cholesterol (HDL-C) is a major risk factor for coronary heart disease (CHD). A secondary prevention study, the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), demonstrated that CHD events were significantly reduced during a median follow-up of 5.1 years by treating patients with the fibric acid derivative gemfibrozil when the predominant lipid abnormality was low HDL-C. OBJECTIVE: To determine if the reduction in major CHD events with gemfibrozil in VA-HIT could be attributed to changes in major plasma lipid levels. DESIGN: Multicenter, randomized, double-blind, placebo-controlled trial conducted from September 1991 to August 1998. SETTING: The Department of Veterans Affairs Cooperative Studies Program, in which 20 VA medical centers were participating sites. PARTICIPANTS: A total of 2531 men with a history of CHD who had low HDL-C levels (mean, 32 mg/dL [0.83 mmol/L] ) and low low-density lipoprotein cholesterol (LDL-C) levels (mean, 111 mg/dL [2.88 mmol/L]). INTERVENTION: Participants were randomly assigned to receive gemfibrozil, 1200 mg/d (n = 1264), or matching placebo (n = 1267). MAIN OUTCOME MEASURE: Relation of lipid levels at baseline and averaged during the first 18 months of gemfibrozil treatment with the combined incidence of nonfatal myocardial infarction and CHD death. RESULTS: Concentrations of HDL-C were inversely related to CHD events. Multivariable Cox proportional hazards analysis showed that CHD events were reduced by 11% with gemfibrozil for every 5-mg/dL (0.13-mmol/L) increase in HDL-C (P =.02). Events were reduced even further with gemfibrozil beyond that explained by increases in HDL-C values, particularly in the second through fourth quintiles of HDL-C values during treatment. During gemfibrozil treatment, only the increase in HDL-C significantly predicted a lower risk of CHD events; by multivariable analysis, neither triglyceride nor LDL-C levels at baseline or during the trial predicted CHD events. CONCLUSIONS: Concentrations of HDL-C achieved with gemfibrozil treatment predicted a significant reduction in CHD events in patients with low HDL-C levels. However, the change in HDL-C levels only partially explained the beneficial effect of gemfibrozil.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Self-citationHigh-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen, V. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050061031 · Cited by 957
Carlson, L. A., & ROSENHAMER, G. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15891.x · Cited by 677
Gotto, A. M., Whitney, E., Stein, E. A., Shapiro, D. R., Clearfield, M., Weis, S., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 563
Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions
McNamara, J. R., & Schaefer, E. J. (1987) · Clinica Chimica Acta · doi:10.1016/0009-8981(87)90188-4 · Cited by 521
Self-citationFruchart, J.-C., Duriez, P., & Staels, B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00007 · Cited by 425
Goldbourt, U., Yaari, S., & Medalie, J. H. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.1.107 · Cited by 391
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.
Miettinen, M., Turpeinen, O., & Karvonen, M. J. (1979) · Heart · doi:10.1136/hrt.42.3.370 · Cited by 360
Genest, J., McNamara, J. R., Ordovas, J. M., Jenner, J. L., Silberman, S. R., Anderson, K. M., Wilson, P. W. F., Salem, D. N., & Schaefer, E. J. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90520-w · Cited by 331
Self-citationRange of serum cholesterol values in the population developing coronary artery disease
Kannel, W. B. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80474-3 · Cited by 289
Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Distribution of lipids in 8,500 men with coronary artery disease
Rubins, H. B., Robins, S. J., Collins, D., Iranmanesh, A., Wilt, T. J., Mann, D., Mayo-Smith, M., Faas, F. H., Elam, M. B., Rutan, G. H., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80761-9 · Cited by 238
Self-citationContois, J. H., McNamara, J. R., Lammi-Keefe, C. J., Wilson, P. W., Massov, T., & Schaefer, E. J. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.4.515 · Cited by 231
Self-citationInfluence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku, K., Gartside, P. S., Hynd, B. A., & Kashyap, M. L. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111879 · Cited by 182
Self-citationMack, W. J., Krauss, R. M., & Hodis, H. N. (1996) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.16.5.697 · Cited by 174
Ruotolo, G., Ericsson, C.-G., Tettamanti, C., Karpe, F., Grip, L., Svane, B., Nilsson, J., de Faire, U., & Hamsten, A. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00442-2 · Cited by 158
Watts, G. F., Mandalia, S., Brunt, J. N. H., Slavin, B. M., COLTART, D. J., & Lewis, B. (1993) · Metabolism · doi:10.1016/0026-0495(93)90199-x · Cited by 146
Lamarche, B., Després, J., Moorjani, S., Cantin, B., Dagenais, G. R., & Lupien, P.-J. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05653-x · Cited by 129
Bloomfield, H. E., Robins, S. J., Iwane, M. K., Boden, W. E., Elam, M. B., Fye, C. L., Gordon, D. J., Schaefer, E. J., Schectman, G., & Wittes, J. T. (1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90708-k · Cited by 99
Self-citationSyvänne, M., Nieminen, M. S., Frick, M. H., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., Ehnholm, C., & Taskinen, M. (1998) · Circulation · doi:10.1161/01.cir.98.19.1993 · Cited by 70
Bloomfield, H. E., Robins, S. J., & Collins, D. E. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00369-4 · Cited by 63
Self-citationMänttäri, M., Koskinen, P., Manninen, V., Huttunen, J. K., Frick, M. H., & Nikkilä, E. A. (1990) · Atherosclerosis · doi:10.1016/0021-9150(90)90054-m · Cited by 39
Franceschini, G., Lovati, M. R., Manzoni, C., Michelagnoli, S., Pazzucconi, F., Gianfranceschi, G., Vecchio, G., & Sirtori, C. R. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05465-u · Cited by 33
McNamara, J. R., Huang, C. M., Massov, T., Leary, E. T., Warnick, G. R., Bloomfield, H. E., Robins, S. J., & Schaefer, E. J. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.2.233 · Cited by 33
Self-citationCabezas, M. C., van Heusden, G. P. H., de Bruin, T. W., van Beckhoven, J. R. C. M., Kock, L. A., WTRTZ, K. W. A., & Erkelens, D. W. (1993) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1993.tb00751.x · Cited by 7
Cited by
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Metadata
- Authors
- Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., Rubins, H. B., & for the VA-HIT Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-03-28
- Volume
- 285
- Issue
- 12
- Pages
- 1585
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2117092539
- Cited by
- 921
- References
- 38
- FWCI
- 61.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.